Baraf H, Fuentealba C, Greenwald M, et al. 2005b. Cardiovascular event rates with etoricoxib and comparator NSAIDs in the edge study and the overall etoricoxib development program [abstract]. Annual Meeting of the European League Against Rheumatism, 8-11 June 2005, Vienna, Austria. SAT0276. Baraf HSB, Fuentealba C, Greenwald M, et al. 2004. Tolerability and effectiveness of etoricoxib compared with diclofenac sodium in patients with osteoarthritis: a randomized controlled study (EDGE trial) [abstract]. American College of Rheumatology 68th Annual Scientific Meeting, 16–21 October 2004, San Antonio, TX, USA. 832. Birbara CA, Puopolo AD, Munoz DR, et al. 2003. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability—a randomized, placebo- controlled, 3-month trial. J Pain, 4:307–15. Boice JA, Ng J, Rubin BR, et al. 2004. The spontaneous resolution of acute gouty arthritis does not significantly contribute to the potent and comparable antiinflammatory and analgesic effect of etoricoxib of indomethacin over the first four days of treatment [abstract]. American College of Rheumatology 68th Annual Scientific Meeting, 16–21 October 2004, San Antonio, TX USA. 809. Bombardier C, Laine L, Reicin A, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med, 343: 1520–8. Bresalier RS, Sandler RS, Quan H, et al. 2005. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352:1092–102. Catella-Lawson F, Reilly MP, Kapoor SC, et al. 2001. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 345:1809–17. Chang DJ, Desjardins PJ, King TR, et al. 2004. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial. Anesth Analg, 99:807–15. Clark DW, Layton D, Shakir SA. 2004. Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology. Drug Saf, 27:427–56. Collantes E, Curtis SP, Lee KW, et al. 2002. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract, 3:10. Curtis SP, Losada B, Bosi-Ferraz M, et al. 2003a. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients [poster]. American College of Rheumatology 67th Annual Scientific Meeting, 23–28 October 2003, Orlando, FL, USA. 213. Curtis SP, Maldonado-Cocco J, Losada BR, et al. 2001. Treatment with etoricoxib (MK-0663), a COX-2-selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis [abstract]. Annual Meeting of the European League Against Rheumatism, 13– 16 June 2001, Prague, Czech Republic. FRI0030. Curtis SP, Bockow B, Fisher C, et al. 2005. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord, 6:58. Curtis SP, Mukhopadhyay S, Ramey D, et al. 2003b. Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum, 48 (Suppl):S616. Curtis SP, Ng J, Yu Q, et al. 2004. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther, 26:70–83. Cush JJ, Kavanaugh A, Matteson EL. 2006. The safety of COX-2 inhibitors. Deliberations from the February 16–18, 2005, FDA meeting [online]. Am Coll Rheumatol. Accessed on 12 January 2006. URL: http:// www.rheumatology.org/publications/hotline/0305NSAIDs.asp. Dallob A, Hawkey CJ, Greenberg H, et al. 2003. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol, 43:573–85. Therapeutics and Clinical Risk Management 2006:2(1) Etoricoxib for arthritis and pain Drazen JM. 2005. COX-2 inhibitors — a lesson in unexpected problems. N Engl J Med, 352:1131–2. [EMEA] European Medicines Agency. 2005a. Etoricoxib summary of product characteristics [online]. Accessed 13 January 2006. URL: http:/ /www.emea.eu.int/pdfs/human/epar/Etoricoxib.pdf. [EMEA] European Medicines Agency. 2005b. Press release: European Medicines Agency concludes action on COX-2 inhibitors [online]. Accessed 13 January 2006. URL: http://www.emea.eu.int/pdfs/human/ press/pr/20776605en.pdf. Fisher C, Bockow B, Curtis SP, et al. 2003. Results of a 190-week randomized study demonstrated similar efficacy of etoricoxib compared with diclofenac in patients with osteoarthritis (OA) [abstract]. Annual Meeting of the European League Against Rheumatism, 18–21 June 2003, Lisbon, Portugal. FRI0256. Fisher CA, Curtis SP, Resnick H, et al. 2001. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks [abstract]. Arthritis Rheum, 44(Suppl 9):S135, 495. FitzGerald GA. 2002. Cardiovascular pharmacology of nonselective non- steroidal antiinflammatory drugs and coxibs: clinical considerations. Am J Cardiol, 89:26D–32D. FitzGerald GA. 2004. Coxibs and cardiovascular disease. N Engl J Med, 351:1709–11. [FDA] Food and Drug Administration. 2001. Consultation NDA 21-042, S-007. Review of cardiovascular safety database: rofecoxib [online]. Accessed 7 July 2005. URL: http://www.fda.gov/ohrms/dockets/ac/ 01/briefing/3677b2_06_cardio.pdf. [FDA] Food and Drug Administration. 2005a. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal antiinflammatory drugs (NSAIDs) [online]. Accessed 24 February 2006. URL: http://www.fda.gov/cder/drug/infopage/COX2.htm. [FDA] Food and Drug Administration. 2005b. COX-2 selective and non- selective non-steroidal antiinflammatory drugs (NSAIDs) [online]. Accessed 7 July 2005. URL: http://www.fda.gov/cder/drug/infopage/ COX2/default.htm. [FDA] Food and Drug Administration. 2005c. FDA presentation: analysis of cardiovascular thromboembolic events with etoricoxib [online]. Accessed 7 July 2005. URL: http://www.fda.gov/ohrms/dockets/ac/ 05/transcripts/2005-4090T2.htm. [FDA] Food and Drug Administration. 2005d. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal antiinflammatory drugs (NSAIDs) [online]. Accessed 23 June 2005. URL: http:// www.fda.gov/cder/drug/advisory/COX2.htm. Frizziero L, Graninger W, Langevitz P, et al. 2004. Etoricoxib is effective in osteoarthritis patients with different levels of baseline severity of the disease [poster]. Annual European Congress of Rheumatology, 9– 12 June 2004, Berlin, Germany. FRI0429. Gossec L, van der HD, Melian A, et al. 2005. The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis, 64:1563–7. Gottesdiener K, Schnitzer T, Fisher C, et al. 2002. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford), 41:1052–61. Hernandez-Garduño A, Vázquez-Leduc A, Querol-Vinagre JV, et al. 2005. Clinical evaluation following treatment with etoricoxib (60, 90 and 120mg once a day) in patients with acute low back pain: a cohort, open, non-randomized, multicenter study [abstract]. Annual Meeting of the European League Against Rheumatism, 8–11 June 2005, Vienna, Austria. SAT0362. Hunsche E, Geling O, Kong SX, et al. 2002. Impact of etoricoxib, a novel COX-2 inhibitor, on social and emotional quality of life of patients with osteoarthritis. Osteoporosis Int, 13:S20. Hunt RH, Harper S, Callegari P, et al. 2003a. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther, 17:201–10. 55